<DOC>
	<DOCNO>NCT00844298</DOCNO>
	<brief_summary>RATIONALE : Nilotinib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving nilotinib together combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well give nilotinib together combination chemotherapy work treat patient newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Nilotinib Combination Chemotherapy Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine clinical efficacy nilotinib combination chemotherapy , term hematologic molecular complete remission ( CR ) rate , patient newly diagnose Philadelphia chromosome-positive acute lymphoblastic leukemia acute mixed lineage leukemia . Secondary - To establish prognostic factor patient treat regimen . - To determine duration CR patient treat regimen . - To determine duration progression-free overall survival patient . - To determine toxicity regimen patient . OUTLINE : This multicenter study . Patients stratify accord age ( 15 64 year vs ≥ 65 year ) . - Induction therapy : Patients receive daunorubicin hydrochloride IV continuously 24 hour day 1-3 , vincristine sulfate IV day 1 8 , oral prednisolone day 1-14 . Patients undergo bone marrow examination day 14 . Patients hematologic remission proceed consolidation therapy . Patients residual leukemic cell &gt; 5 % receive additional dose daunorubicin hydrochloride IV continuously 24 hour day 15 proceed consolidation therapy . - Consolidation therapy : For course 1 , patient receive daunorubicin hydrochloride IV continuously 24 hour day 1 2 , vincristine sulfate IV day 1 8 , oral prednisolone day 1-14 . For course 2 4 , patient receive cytarabine IV 2 hour etoposide IV 3 hour day 1-4 . For course 3 5 , patient receive methotrexate IV continuously 36 hour day 1 , 2 , 15 , 16 leucovorin calcium IV every 6 hour 3 dos orally blood methotrexate level safe range . Patients also receive oral nilotinib twice daily begin day 8 induction therapy continue completion consolidation therapy . After completion consolidation therapy , patient hematopoietic stem cell donor proceed allogeneic hematopoietic stem cell transplantation ( HSCT ) . Patients undergo HSCT continue receive oral nilotinib twice daily 2 year completion consolidation therapy . After completion study therapy , patient follow periodically 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute lymphoblastic leukemia acute mixed lineage leukemia Positive BcrAbl fusion transcript ( Philadelphia chromosomepositive disease ) RTPCR PATIENT CHARACTERISTICS : ECOG performance status 02 Total bilirubin &lt; 2 mg/dL SGOT &lt; 3 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN ( unless consider tumorrelated ) Creatinine &lt; 2.0 mg/dL ULN Serum amylase lipase ≤ 1.5 time ULN Potassium , magnesium , phosphorus normal ( supplementation allow ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No rare hereditary problem galactose intolerance , severe lactase deficiency , glucosegalactose malabsorption No known sensitivity study drug No severe medical condition , opinion investigator , would preclude study participation No impaired cardiac function , include follow : LVEF &lt; 45 % low limit normal ECHO Long QT syndrome know family history long QT syndrome Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTc &gt; 450 msec baseline ECG ( use QTcF formula ) Myocardial infarction within past 12 month Other clinically significant heart disease , include follow : Unstable angina Congestive heart failure Uncontrolled hypertension Uncontrolled arrhythmias No primary malignant disease require systemic treatment No acute chronic liver , pancreatic , severe renal disease No severe and/or lifethreatening medical disease No history significant congenital acquire bleed disorder unrelated cancer No impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug No history noncompliance PRIOR CONCURRENT THERAPY : More 30 day since prior investigational agent No concurrent medication potential prolong QTc interval No concurrent strong CYP3A4 inhibitor No concurrent therapeutic coumarin derivative</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
</DOC>